Selected article for: "clinical practice and cumulative mortality"
Author: Pafundi, Pia Clara; Galiero, Raffaele; Simeon, Vittorio; Rinaldi, Luca; Perrella, Alessandro; Vetrano, Erica; Caturano, Alfredo; Alfano, Maria; Beccia, Domenico; Nevola, Riccardo; Marfella, Raffaele; Sardu, Celestino; Coppola, Carmine; Scarano, Ferdinando; Maggi, Paolo; De Lucia Sposito, Pellegrino; Vocciante, Laura; Rescigno, Carolina; Sbreglia, Costanza; Fraganza, Fiorentino; Parrella, Roberto; Romano, Annamaria; Calabria, Giosuele; Polverino, Benedetto; Pagano, Antonio; Bologna, Carolina; Amitrano, Maria; Esposito, Vincenzo; Coppola, Nicola; Maturo, Nicola; Adinolfi, Luigi Elio; Chiodini, Paolo; Sasso, Ferdinando Carlo
Title: Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study
  • Cord-id: jw1d6kel
  • Document date: 2021_9_14
    • ID: jw1d6kel
    Snippet: INTRODUCTION: During COVID-19 pandemic, the use of several drugs has represented the worldwide clinical practice. However, though the current increase of knowledge about the disease, there is still no effective treatment for the usage of drugs. Thus, we retrospectively assessed use and effects of therapeutic regimens in hospitalized patients on in-hospital mortality. METHODS: COVOCA is a retrospective observational cohort study on 18 COVID centres throughout Campania Region Hospitals. We include
    Document: INTRODUCTION: During COVID-19 pandemic, the use of several drugs has represented the worldwide clinical practice. However, though the current increase of knowledge about the disease, there is still no effective treatment for the usage of drugs. Thus, we retrospectively assessed use and effects of therapeutic regimens in hospitalized patients on in-hospital mortality. METHODS: COVOCA is a retrospective observational cohort study on 18 COVID centres throughout Campania Region Hospitals. We included adult patients with confirmed SARS-CoV-2 infection, discharged/dead between March/June 2020. RESULTS: 618 patients were included, with an overall in-hospital cumulative mortality incidence of 23.1%. Most prescribed early treatments were antivirals (72%), antibiotics (65%) and hydroxychloroquine/anticoagulants (≈50%). Tocilizumab, indeed, was largely prescribed late during hospitalization. Multivariable models, with a cut-off at day 2 for early COVID-19 therapy administration, did not disclose any significant association of a single drug administration on the clinical outcome. DISCUSSION: COVOCA represents the first multicenter database in Campania region. None drug class used during the pandemic significantly modified the outcome, regardless of therapy beginning, both overall and net of those already in non-invasive ventilation (NIV)/ orotracheal intubation (OTI) at hospitalization. Our cumulative incidence of mortality seems lower than other described during the same period, particularly in Northern Italy.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and admission date: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and admission date symptom: 1
    • acute respiratory syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission day early: 1, 2
    • acute respiratory syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission respiratory support: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and local ethics committee: 1, 2, 3, 4
    • acute respiratory syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • administration relate and local ethics committee: 1
    • administration time and liver disease: 1
    • administration time and lmwh low molecular weight heparin: 1
    • administration time and local ethics committee: 1
    • administration time and logistic regression model: 1
    • admission date and logistic regression model: 1, 2
    • admission day and lmwh low molecular weight heparin: 1, 2
    • admission day and local ethics committee: 1, 2
    • admission day and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19